Journal Mobile Options
Table of Contents
Vol. 27, No. 3, 2009
Issue release date: September 2009
Section title: Differences in the Diagnostic Procedures
Dig Dis 2009;27:259–268
(DOI:10.1159/000228559)

What Is the Role of Serological Markers in IBD? Pediatric and Adult Data

Dubinsky M.
Pediatric IBD Center, Cedars-Sinai Medical Center, David Geffen School of Medicine, Los Angeles, Calif., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Differences in the Diagnostic Procedures

Published online: 9/24/2009

Number of Print Pages: 10
Number of Figures: 2
Number of Tables: 0

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: http://www.karger.com/DDI

Abstract

Physicians rely heavily on the presence of disease markers to support or even at times modify their clinical impression for certain diseases that can only be diagnosed clinically. Typically these markers play an important role in helping to establish a diagnosis and to evaluate the activity of a chronic disease over time. The diagnosis of inflammatory bowel disease (IBD), however, is not based solely on clinical grounds. Invasive endoscopic and radiological as well as histopathological criteria need to be met in order to make a correct diagnosis and differentiate disease subtypes. The search for novel diagnostic approaches that accurately distinguishes a group of patients with IBD from those unaffected by the disease has become a focus in IBD research. This search, however, has taken a very exciting turn in the direction of finding biologic and genetic markers that can assess the natural history and predict the course of individual’s disease including response to treatments over time.


Article / Publication Details

First-Page Preview
Abstract of Differences in the Diagnostic Procedures

Published online: 9/24/2009

Number of Print Pages: 10
Number of Figures: 2
Number of Tables: 0

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: http://www.karger.com/DDI


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Duchmann R, May E, Heike M, Knolle P, Neurath M, Meyer zum Buschenfelde KH: T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident luminal flora in humans. Gut 1999;44:812–818.
  2. Vidrich A, Lee J, James E, Cobb L, Targan S: Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J Clin Immunol 1995;15:293–299.
  3. Eggena M, Cohavy O, Parseghian MH, Hamkalo BA, Clemens D, Targan SR, Gordon LK, Braun J: Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. J Autoimmun 2000;14:83–97.
  4. Cohavy O, Harth G, Horwitz M, Eggena M, Landers C, Sutton C, Targan SR, Braun J: Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn’s disease. Infect Immunol 1999;67:6510–6517.
  5. Seibold F, Brandwein S, Simpson S, Terhorst C, Elson CO: pANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol 1998;18:153–160.
  6. Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, Targan SR, Braun J: Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immunol 2000;68:1542–1548.
  7. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG: Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998;115:822–829.
  8. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D: Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788–791.
  9. Hoffenberg EJ, Fidanza S, Sauaia A: Serologic testing for inflammatory bowel disease. J Pediatr 1999;134:447–452.
  10. Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shanahan F: Anti-neutrophil cytoplasmic antibodies in ulcerative colitis: comparison with other colitides/diarrheal illnesses. Gastroenterology 1991;100:1590–1596.
  11. Proujansky R, Fawcett PT, Gibney KM, Treem WR, Hyams JS: Examination of anti-neutrophil cytoplasmic antibodies in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993;17:193–197.
  12. Winter HS, Landers CJ, Winkelstein A, Vidrich A, Targan SR: Anti-neutrophil cytoplasmic antibodies in children with ulcerative colitis. J Pediatr 1994;125:707–711.
  13. Oberstadt K, Schaedel W, Weber M, Classen M, Deusch K: P-ANCA as a differential diagnostic marker in inflammatory bowel disease. Adv Exp Med Biol 1995;371B:1313–1316.
  14. Sendid B, Colombel JF, Jacquinot PM, Faille C, Fruit J, Cortot A, Lucidarme D, Camus D, Poulain D: Specific antibody response to oligomannosidic epitopes in Crohn’s disease. Clin Diagn Lab Immunol 1996;3:219–226.
  15. Mallant-Hent RC, Mooij M, von Blomberg BM, Linskens RK, van Bodegraven AA, Savelkoul PH: Correlation between Saccharomyces cerevisiae DNA in intestinal mucosal samples and anti-Saccharomyces cerevisiae antibodies in serum of patients with IBD. World J Gastroenterol 2006;12:292–297.
  16. Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, Weishauss O, Spector L, Shtevi A, Altstock RT, Dotan N, Halpern Z: Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn’s disease. Gastroenterology 2006;131:366–378.
  17. Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, Targan SR: Selected loss of tolerance evidenced by Crohn’s disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002;123:689–699.
  18. Beaven SW, Abreu MT: Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol 2004;20:318–327.
  19. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JI, Yang H, Targan SR: Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology 2004;126:414–424.
  20. Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, Satsangi J: Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004;99:2376–2384.
  21. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO, Hershberg RM: Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology 2005;128:2020–2028.
  22. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, Fort M, Hershberg RM: Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004;113:1296–1306.
  23. Peeters M, Joossens S, Vermeire S, et al: Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001;96:730–734.
  24. Hoffenberg EJ, Fidanza S, Sauaia A: Serologic testing for inflammatory bowel disease. J Pediatr 1999;134:447–452.
  25. Dubinsky MC, Ofman JJ, Urman M, Targan SR, Seidman EG: Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2001;96:758–765.
  26. Dubinsky MC, Johanson JF, Seidman EG, Ofman JJ: Suspected inflammatory bowel disease: the clinical and economic impact of competing diagnostic strategies. Am J Gastroenterol 2002;97:2333–2342.
  27. Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A: Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn’s disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004;99:2235–2241.
  28. Yu CS, Pemberton JH, Larson D: Ileal pouch-anal anastomosis in patients with indeterminate colitis: long-term results. Dis Colon Rectum 2000;43:1487–1496.
  29. Panaccione R, Sandborn WJ: Is antibody testing for inflammatory bowel disease clinically useful? Gastroenterology 1999;116:1001–1002; discussion 1002–1003.
  30. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D: Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788–791.
  31. Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW, Tekkis PP: Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006;101:2410–2422.
  32. Joossens S, Reinisch W, Vermeire S, et al: The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002;122:1242–1247.
  33. Joossens S, Colombel JF, Landers C, Poulain D, Geboes K, Bossuyt X, Targan S, Rutgeerts P, Reinisch W: Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut 2006;55:1667–1669.
  34. Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, Rotter JI, Vidrich A, Targan SR: Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn’s disease define a clinical subgroup. Gastroenterology 1996;110:1810–1819.
  35. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR: Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47:487–496.
  36. Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, Almer S, Tysk C, O’Morain C, Gassull M, Binder V, Finkel Y, Modigliani R, Gower-Rousseau C, Macry J, Merlin F, Chamaillard M, Jannot AS, Thomas G, Hugot JP: CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002;70:845–857.
  37. Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR, Crawshaw J, Large O, de Silva A, Cook JT, Barnardo M, Cullen S, Welsh KI, Jewell DP: The molecular classification of the clinical manifestations of Crohn’s disease. Gastroenterology 2002;122:854–866.
  38. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG: The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002;122:867–874.
  39. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H: Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology 2002;123:679–688.
  40. Forcione DG, Rosen MJ, Kisiel JB, Sands BE: Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn’s disease. Gut 2004;53:1117–1122.
  41. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JI, Yang H, Targan SR: Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology 2004;126:414–424.
  42. Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, Satsangi J: Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004;99:2376–2384.
  43. Xue S, Stempak JM, Elkadri AA, Greenberg GR, Walters TD, Griffiths AM, Steinhart H, Silverberg MS: Serological markers are associated with severity of disease and need for surgery in IBD patients. Gastroenterology 2006;130:S1303.
  44. Desir B, Amre DK, Lu SE, Ohman-Strickland P, Dubinsky M, Fisher R, Seidman EG: Utility of serum antibodies in determining clinical course in pediatric Crohn’s disease. Clin Gastroenterol Hepatol 2004;2:139–146.
  45. Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Quiros A, Vasiliauskas EA, Grill B, Israel D, Bahar R, Christie D, Wahbeh G, Silber G, Dallazadeh S, Shah P, Thomas D, Kelts D, Hershberg RM, Elson CO, Targan SR, Taylor KD, Rotter JI, Yang H: Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol 2006;101:360–367.
  46. Dubinsky MC, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel I, Quiros JA, Silber G, Wahbeh G, Vasiliauskas EA, Bahar RJ, Otley A, Mack DR, Evans J, Rosh JR, Oliva Hemker M, Leleiko NS, Crandall WV, Langton C, Taylor KD, Targan SR, Rotter JI, Markowitz JF, Hyams JS: Increased immune reactivity predicts aggressive complicating Crohn’s disease in children. Gastroenterology 2007;132:A17.

    External Resources

  47. Amre DK, Lu SE, Costea F, Seidman EG: Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn’s disease patients. Am J Gastroenterol 2006;101:645–652.
  48. Devlin SM, Yang H, Ippoliti A, Taylor KD, Landers CJ, Su X, Abreu MT, Papadakis KA, Vasiliauskas EA, Melmed GY, Fleshner PR, Mei L, Rotter JI, Targan SR: NOD2 variants and antibody response to microbial antigens in Crohn’s disease patients and their unaffected relatives. Gastroenterology 2007;132:576–586.
  49. Cruyssen BV, Peeters H, Hoffman IE, Laukens D, Coucke P, Marichal D, Cuvelier C, Remaut E, Veys EM, Mielants H, De Vos M, De Keyser F: CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in Caucasian Crohn’s disease patients. Clin Exp Immunol 2005;140:354–359.
  50. Annese V, Lombardi G, Perri F, D’Inca R, Ardizzone S, Riegler G, Giaccari S, Vecchi M, Castiglione F, Gionchetti P, Cocchiara E, Vigneri S, Latiano A, Palmieri O, Andriulli A: Variants of CARD15 are associated with an aggressive clinical course of Crohn’s disease: an IG-IBD study. Am J Gastroenterol 2005;100:84–92.
  51. Ippoliti AF, Devlin S, Yang H, Mei L, Papadakis K, Vasiliauskas E, Melmed G, Shaye O, Enyati G, Chen J, Nataskin I, Patel Y, Mehdikhani E, Taylor KD, Landers C, Rotter JI, Targan S: The relationship between abnormal innate and adaptive immune function and fibrostenosis in Crohn’s disease patients. Gastroenterology 2006;130:A127.

    External Resources

  52. Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Norman G, Szamosi T, Papp J, Lakatos P: New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15genotype in a Hungarian IBD cohort. Am J Gastroenterol 2008;103:665–681.
  53. Fleshner PR, Vasiliauskas EA, Kam LY, Fleshner NE, Gaiennie J, Abreu-Martin MT, Targan SR: High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 2001;49:671–677.
  54. Fleshner P, Vasiliauskas E, Dubinsky M, Mei L, Landers C, Ippoliti A, Papadakis K, Targan S: Both preoperative pANCA and CBir1 flagellin expression in ulcerative colitis (UC) patients influence pouchitis development after ileal pouch-anal anastamosis (IPAA). Gastroenterology 2006;130:A130.
  55. Melmed GY, Fleshner PR, Bardakcioglu O, Ippoliti A, Vasiliauskas EA, Papadakis KA, Dubinsky M, Landers C, Rotter JI, Targan SR: Family history and serology predict Crohn‘s disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2008;51:100–108.
  56. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR: ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn’s disease. Gastroenterology 2001;120:1347–1355.
  57. Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, Poulain D, Bossuyt X, Rutgeerts P, Belgian Group of Infliximab Expanded Access Program in Crohn’s Disease: Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s disease. Am J Gastroenterol 2002;97:1458–1462.
  58. Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes JK, Rutgeerts P: Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007;13:123–128.
  59. Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, Shoenfeld Y: Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005;54:1232– 1236.
  60. Sutton CL, H Yang, Li Z, Rotter JI, Targan SR, Braun J: Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn’s disease. Gut 2000;46:58–63.
  61. Halfvarson J, Standaert-Vitse A, Järnerot G, Sendid B, Jouault T, Bodin L, Duhamel A, Colombel JF, Tysk C, Poulain D: Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut 2005;54:1237–1243.
  62. Mei L, Targan SR, Landers CJ, Dutridge D, Ippoliti A, Vasiliauskas EA, Papadakis K, Fleshner PR, Rotter JI, Yang HY: Familial expression of anti-Escherichia coli outer membrane porin (OmpC) in relatives of patients with Crohn’s disease. Gastroenterology 2006;130:1078–1085.
  63. Dubinsky M, Mei L, Landers C, Katzir L, Farrior S, Wrobel I, Quiros A, Bahar R, Wahbeh G, Grill B, Silber G, Pietzak M, Vasiliauskas E, Dallazadeh S, Kelts D, Elson C, Hershberg R, Huiying Y, Targan S, Rotter J, Western Regional Pediatric IBD Research Alliance, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; University of Alabama, Birmingham, AL; Dendreon Corporation, Seattle, WA: Familial expression of serological immune responses in pediatric IBD. J Pediatr Gastroenterol Nutr 2005;41:A150.